Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy: A Cost-Minimization Analysis

Roberto Ravasio, Cinzia Ortega, Roberto Sabbatini, Camillo Porta

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy: A Cost-Minimization Analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences